Investigational drug · Phase 3
zorevunersen
Also called: STK-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dravet Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "zorevunersen"
First trial start
2021
Jan 20, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zorevunersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dravet Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "zorevunersen" as an intervention, largest first.
- A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromePivotal-lookingActive, not recruiting
Stoke Therapeutics, IncIndustry
NCT06872125 · 170 participants (planned) · Start Jun 4, 2025 · Primary completion Mar 2027
Drug: zorevunersen · For: Dravet Syndrome
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 61 sites in all
- An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeActive, not recruiting
Stoke Therapeutics, IncIndustry
NCT04740476 · 60 participants (planned) · Start Jan 20, 2021 · Primary completion Mar 31, 2029
Drug: zorevunersen (STK-001) · For: Dravet Syndrome
Sites: San Francisco, California; Aurora, Colorado; Washington D.C., District of Columbia · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antisense Oligonucleotidesin Genetic Epilepsies and Developmental and Epileptic Encephalopathies: Molecular Mechanisms, Translational Evidence and Disease-Modifying Potential.
Leo A, Roberti R, Vono PF, et al. · Biology (Basel) 2026
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Sodium Channel Blocker Tolerance as a Metric for Disease Modification in Dravet Syndrome.
Yuji K, Yuji W · Ann Child Neurol Soc 2026
- At the forefront of gene-based therapies in Dravet syndrome.
Riva A, Di Gioacchino S, Volpedo G, et al. · Expert Opin Emerg Drugs 2026
- Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.
Martins WA · Curr Issues Mol Biol 2026
- Zorevunersen in Children and Adolescents with Dravet Syndrome. Reply.
Laux L, Ticho B, Cross JH · N Engl J Med 2026
Also in development for Dravet Syndrome
- LP352bexicaserinPhase 34 trials
Longboard Pharmaceuticals · Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Clemizole HClEPX-100Phase 32 trials
Epygenix · Dravet Syndrome, Lennox Gastaut Syndrome
- ETX101Phase 23 trials
Encoded Therapeutics · Dravet Syndrome
- BMB-101Phase 22 trials
Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome
- ION337Phase 21 trial
Ionis Pharmaceuticals · Dravet Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.